chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Tachycardia (115-123 bpm via pulse oximeter) even at rest that started about three hours following inoculation of the second Pfizer COVID-19 vaccine that persisted for about 16-18 hours. It did cause some sleep disturbance in the middle of the night about 15-16 hrs post-inoculation at approximately 3-4:00 a.m. that woke me up in my sleep secondary to feelings of palpitations. This kind of resting tachycardia has resolved spontaneously without any treatments. No fever, chest pain, shortness of breath, extremity swelling, rash. I did have body aches for about three days following inoculation, but that is normal with this vaccine.   However, I cannot say my tachycardia has fully resolved yet. It is complicated by the fact that I developed tachycardia following my orthognathic surgery in November 2020, which I have never experienced before in my life as I am generally healthy without any past medical history. This appeared to have went away temporarily a week before I had this second COVID-19 vaccine (roughly six months post-op) and then came back three hours after being inoculated. It made sense in the beginning  as I was hypovolemic and dehydrated and could not eat or drink anything that well, but it still did not go away months after the procedure with increased fluid intake (averaging 2-3 L/day) and eating normally overall. I did speak to my surgeon about this in April 2021, where I did mention that my tachycardia appeared to be worsened with transitioning, suggestive of orthostasis, but upon further observation, it is worsened with just daily/strenuous activities (e.g. short walking distances, lifting and moving a small table, anything strenuous really). His assessment and plan  in his chart notes was as follows:  "A/p   Doing well from an orthognathic surgical standpoint.  She has recovered as expected and the result is optimal.   With respect to her tachycardia, this sounds like orthostasis, although she is adamant that she is well hydrated.  Other things on the differential would include cardiac (unlikely, she is young and healthy and doesn't have any other symptoms), adrenal insufficiency (she did receive corticosteroids immediately after surgery, but this should not have been enough to cause insufficiency), infection (no signs or symptoms), medication related (unlikely, no new meds), or neurogenic causes (also unlikely).  As all of these are unlikely, and it is unlikely to be associated with the surgery, I am at a loss as to what might be the cause.  I advised she establish care with a PCP and get this worked up, should it continue. She agrees."
gave pt the vaccine and pt did fine. went to give a couple of vaccines to other family members and pt started stating feeling dizzy and helped pt sat down. pt's pulse was fine, was still breathing and was someone alert to voices but not responding. pt was responsive and alert after family member applied some cold water to pt's face and felt fine afterward over the course of 2-4 minutes. pt had same vaccine the previous year with no reaction.
This spontaneous report as received from a consumer refers to a 60 years old female patient with prevent shingles. The patient was vaccinated with dose 1 ZOSTAVAX on 18-AUG-2011. No other co-suspects were reported. Concomitant medications included levothyroxine sodium and CEPHALEX. On 10-NOV-2012 the patient experienced shingles, 451 days after onset of therapy. The patient experienced a band at waist on left front and around to the back side also. The blisters occurred on the 12-NOV-2012, and she is still experiencing the pain in nerve endings around the waist line. The patient also felt she was developing a head cold around 15-NOV-2012 along with a low grade fever that lasted through 17-NOV-2012. The patient was diagnosed with shingles at a walk-in clinic on 17-NOV-2012. The patient was treated with antiviral, Valacyclovir. The outcome of shingles is unknown. The relatedness for shingles is unknown for ZOSTAVAX. Additional information has been requested.
Information has been received from a consumer concerning her friend who on an unspecified date was vaccinated with a dose of MMR II (Lot # not provided). The consumer stated that her friend had "a reaction" to MMR II. At the time of this report, the patient's outcome was unknown. It was unknown if the patient sought medical attention. This is one of several reports received from the same source. No further information is available.
Patient reported symptoms of dizziness, weakness and feeling extremely cold. symptoms started after midnight.(same day as vaccination given) lasted for 6-8 hours then felt fine in the AM Patient reported the same symptoms after the 2 shot (given 8/22/2019) but did not last as long(about 3 hrs ) Patient reported this reaction on 8/22/2019 when getting 2nd shot. She called back to say it happened again after 2nd shot
Myalgia, Fever,  muscle aches, joint pain, fever, fatigue  Narrative: employee states: unable to come to work Friday (day after vaccination) due to muscle aches. joint pain, fever, and fatigue.
sore/achy; she had fever of 101; Body chills; lymph node reaction everywhere; sore arm; burning immediately at site; This is a spontaneous report from a contactable consumer (patient). A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0150) via an unspecified route of administration in the left arm on 07Apr2021 at 17:15 (at the age of 49-years-old) as dose 2, single for COVID-19 immunisation. Medical history included paroxysmal atrial fibrillation (reported as Paroxmal afib), supraventricular tachycardia (SVT), graves' disease and hashimoto's disease. Concomitant medications taken within two weeks prior to vaccination included levothyroxine sodium (TIROSINT), via unspecified route of administration from unknown date to unknown date at unknown dose and frequency for an unspecified indication; hydrochlorothiazide (HCTZ) (reported as hgtz), via unspecified route of administration from unknown date to unknown date at unknown dose and frequency for an unspecified indication; atenolol (ATENOL), via unspecified route of administration from unknown date to unknown date at unknown dose and frequency for an unspecified indication; vitamin d nos (VITAMIN D), via unspecified route of administration from unknown date to unknown date at unknown dose and frequency for an unspecified indication and potassium (MANUFACTURER UNKNOWN), via unspecified route of administration from unknown date to unknown date at unknown dose and frequency for an unspecified indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6199) via an unspecified route of administration in the left arm on 17Mar2021 at 17:15 (at the age of 48-years-old) as a dose 1, single for COVID-19 immunisation and had got a raised red bump for a day. The patient was not a pregnant at the time of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 at 17:15, when given the second shot of injection the patient had a burning immediately at site. On 08Apr2021 (next day), the patient woke up sore arm and but sore by 15:30 she had fever of 101, Body chills, achy and lymph node reaction everywhere. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The patient underwent lab tests which included body temperature with 101 (units unspecified) on 08Apr2021 fever of 101. The clinical outcome of the events were recovering.  No follow-up attempts are needed. No further information is expected.
patient had a headache, felt very dizzy and "jittery" after her vaccine - did wait the 15 minutes but after about 15 more minutes needed to sit down again
Pt. was administered the Menactra vaccine on the morning of 9/16/08. When he picked up his wife at 1pm he c/o sore throat. At 8:30-9 pm he also had fever. At 2am wife woke up and noticed pt. was breathing shallow and was "on fire" with a temp of 103F. Pt. c/o feeling weak and couldn't get out of bed. Wife called 911 and pt. was taken to ER with HR of 172. He was treated and released from ER after about 3 1/2 hours. Pt. saw his primary doctor the next day. Doctor ordered him to stay home from school until Monday, 9/22. Sore throat and low grade fever lasted through Saturday. Fever was tx'd with tylenol druing this time as ordered by PMD.
patient vaccinated on 08/24/19 / and the second dose is not administered yet; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 24th August 2019, batch number 2G2T7, expiry date 15th November 2021).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. The VAERS details were reported for 1st dose of Shingrix. The reporter consented to follow up. This case has been linked with US2021152864 and US2021152856, reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021152864:Same reporter US-GLAXOSMITHKLINE-US2021152856:Same reporter
employee received vaccine, approx 20 min later felt her throat getting tight she was taked to the ED via WC.  She reported that her heart rate was 130 she received benadryl, pepcid, refused the steroid they offered.  Waited and then returned to work after dc from ED.  labs were drawn in ED.   She recently had covid-19 but had recovered and symptoms were gone for some time.
WEB TOES AND FINGERS; This spontaneous report received from a patient via a company representative from Social media concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination.The batch number was not reported. Per procedure, no follow up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the patient had web toes and fingers. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from web toes and fingers. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20210635942-COVID-19 VACCINE AD26.COV2.S-Web toes and fingers . This event(s) is considered not related. The event(s) is deemed to be scientifically implausible, i.e., there is scientific evidence against a drug/event relationship; AND there is no known class effect.
Information has been received from a pharmacist concerning a patient who was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine in the tissue rather than in the muscle and the area puffed up. The patients outcome was unknown. Unspecified medical attention was sought. No lot number or additional information was provided. No product quality complaint was involved. Additional information has been requested.
This is a non-serious cluster of 2 patients who experienced adverse events following administration of FLUZONE Intradermal (lot number not reported). Initial report was received on 31 October 2011 from a health care provider. Two patients (age and date of birth not reported) had received FLUZONE Intradermal, (lot number, route and site of administration were not reported). One of the patients an employee at a dental clinic experienced a bad reaction to the intradermal injection. The second patient ended up in the emergency room (ER) with swelling down to the elbow. No further informational was available at the time of the report. The patient's outcome was not reported. Follow-up information received from a health care professional on 20 January 2012. It was clarified by the reported that a cluster of 4 patients (previously reported as 2 patients) had received FLUZONE Intradermal (lot number UT4163AA) on different days and experienced reactions. This case will now be the case of reference for 1 of the 4 patients who had been identified as a 43 year-old female patient who is discussed below. Due to the follow-up information received on this patient this case now meets seriousness criteria and has been upgraded to serious. Information regarding the other 3 patients (all non-serious cases) are captured in case numbers 2012-00783, 00784, 00785. A 43-year-old female patient who had concurrent illnesses of upper respiratory infection (URI), had received a left arm injection of FLUZONE Intradermal (lot number UT4163AA) on 27 October 2011 at 3 pm, and 2 days later on 29 October 2011 at 3:30 pm reported swelling down to the elbow. The patient presented to the emergency room and was administered steroid injection and antibiotics for arthus reaction. Concomitant medications included B12 injection. The patient recovered on an unspecified date. Documents held by sender: none.
Systemic: Dizziness / Lightheadness-Medium, Systemic: Fainting / Unresponsive-Mild, Additional Details: patient received a covid booster and flu shot. immediately after her flu shot she fainted and lost conciousness for about 1 minute. When she awoke she said she was fine. family reported a history of fainting but not during vaccination. The patient reported not eating and being nervous.
Itching; Rash; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itching) and RASH (Rash) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Feb-2021, the patient experienced PRURITUS (Itching) and RASH (Rash). At the time of the report, PRURITUS (Itching) and RASH (Rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product used was not provided by the reporter. Treatment information was not provided.   This case was linked to -MOD-2021-092534 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 27-Apr-2021: Follow-up received on 27-Apr-2021 included no new information.; Sender's Comments:  -MOD-2021-092534:2nd dose case
RECEIVED FLU VACCINE; CANNOT LIFT ARM BUT A SMALL AMOUNT.ARM THROBS; CAN ONLY MOVE ARM STRAIGHT. HURT FROM TIME VACCINE GIVEN. TAKING IBUPROFEN AND USING HOT AND COLD COMPRESSES.
left arm pain; pain on the back; muscle weakness; pain under the arm; joint pain/shoulder pain; muscle pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (left arm pain), BACK PAIN (pain on the back), MUSCULAR WEAKNESS (muscle weakness), AXILLARY PAIN (pain under the arm) and ARTHRALGIA (joint pain/shoulder pain) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 20-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (left arm pain), BACK PAIN (pain on the back), MUSCULAR WEAKNESS (muscle weakness), AXILLARY PAIN (pain under the arm), ARTHRALGIA (joint pain/shoulder pain) and MYALGIA (muscle pain). At the time of the report, PAIN IN EXTREMITY (left arm pain), BACK PAIN (pain on the back), MUSCULAR WEAKNESS (muscle weakness), AXILLARY PAIN (pain under the arm), ARTHRALGIA (joint pain/shoulder pain) and MYALGIA (muscle pain) had not resolved.            Concomitant medication was not provided. Treatment information was not provided.  After the second dose of vaccination patient has had left arm pain, then pain under the arm and on the back, joint pain, muscle pain, muscle weakness and shoulder pain. Still having all of these symptoms after 8 months.
Covid monitoring documentation. PT admitted 11/24/21 documented to have positive covid. PT received Janssen 3/5/21 Lot 1802068 for dose 1.
Systemic itching: current. Shortness of breath (SOB): 1st week. Redness in face: 1st - 2nd week.
Information has been received from a licensed practical nurse concerning a 2 month old female who on 27-AUG-2007 was vaccinated with her first dose of Rotateq (lot# 657522/0769U).  On 28-AUG-2007 the patient developed diarrhea that has persisted to 11-SEP-2007.  Unspecified medical attention was sought.  No cultures or lab tests were performed.  As of 11-SEP-2007 the patient's diarrhea persisted.  There was no product quality complaint.  Additional information has been requested.
Tired, shoulder pain and decrease range of movement. Bruising, itchy, lump mout sores
pt recv vax APR(7 & pt devel lt ankle edema that was similar to a blood clot & exp pain up to knee;pt was treated w/heparin;pt testes positive for rheumatoid arthritis;
Patient developed cellulitis in the evening of 10/4/18, the day of the vaccination, feeling sick, labored breathing, fever, swelling, - went to the doctor the weekend of 10/5/18. Was sent to the ER - low blood pressure of 84/38, high pulse rate >120, admitted at the hospital on Sunday 10/7/18, discharged Tuesday 10/9/18.
Devel lump & swelling in inject site, lump in neck, pain (extreme) in lt arm where vax given, fever (degree unk); From several hrs p/vax gradually relieved by APAP & cold compresses over next 2-3 days;
Flu like symptoms; weak/tired Covid-19 feeling; weak/tired Covid-19 feeling; very nauseated; Fever; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms), ASTHENIA (weak/tired Covid-19 feeling), FATIGUE (weak/tired COVID-19 feeling), NAUSEA (very nauseated) and PYREXIA (Fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms), ASTHENIA (weak/tired COVID-19 feeling), FATIGUE (weak/tired Covid-19 feeling), NAUSEA (very nauseated) and PYREXIA (Fever). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms), ASTHENIA (weak/tired Covid-19 feeling), FATIGUE (weak/tired Covid-19 feeling), NAUSEA (very nauseated) and PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications were not provided. Treatment information was not provided.   Reporter did not allow further contact
One week later mom brought pt for red sore leg pt had abscess and cellulitis at hib vaccine injection site-required I&D of abscess, IV abx and hospitalization. Medical record on 04/28/04 states: Per review of lab results medical records, there are no new COSTARTS.  Nurse follow up on 05/25/04 states: add fever.
1 inch red, indurated area at site of varicella injection.  No systemic symptoms.
shortness of breath; sweating more than normal; more tired than usual; nausea/vomiting; nausea/vomiting; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (shortness of breath), HYPERHIDROSIS (sweating more than normal), FATIGUE (more tired than usual), NAUSEA (nausea/vomiting) and VOMITING (nausea/vomiting) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Mar-2021, the patient experienced DYSPNOEA (shortness of breath), HYPERHIDROSIS (sweating more than normal), FATIGUE (more tired than usual), NAUSEA (nausea/vomiting) and VOMITING (nausea/vomiting). On 17-Mar-2021, DYSPNOEA (shortness of breath), HYPERHIDROSIS (sweating more than normal), FATIGUE (more tired than usual), NAUSEA (nausea/vomiting) and VOMITING (nausea/vomiting) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter Treatment information was not provided
Headache,  injection site swelling and pain, nausea, general fatigue, and slight dizziness.
Red area appeared on upper left arm around injection site, then  another warm red area the size of a dollar bill appeared mid-humerus.  Instructed to take Benadryl and used cool compresses.
Since I've had my shot for shingles many years ago, I've only had a few mind cases/Suspected vaccination failure; Since I've had my shot for shingles many years ago I've only had a few mind cases; stress; illness; This case was reported by a consumer via Shingles interactive digital media and described the occurrence of Suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine).   On an unknown date, the patient received Shingle's vaccine. On an unknown date, unknown after receiving Shingle's vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, stress and illness. On an unknown date, the outcome of the vaccination failure, shingles, stress and illness were unknown.   It was unknown if the reporter considered the vaccination failure, shingles, stress and illness to be related to Shingle's vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The patient had Shingles shot many years ago and had few mild cases and it was from stress or illness. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, laboratory confirmation and time to onset of shingles were unknown at the time of reporting.  Note: It was reported that the patient had few mind cases, but it seems to be typo error and thus it was considered as mild case. Hence by considering worst case approach shingles was captured as event and also stress and illness captured as event conservatively.